Ivabradine in the treatment of heart failure with reduced ejection fraction

26 May 2018 (00:00 - 00:00)

Organised by:

Sign in to view the resources

About the speaker

Doctor Gulnaz Dadashova

Scientific Research Institute of Cardiology, Baku (Azerbaijan)

46 More presentations in this session

Presentation thumbnail

Cardiopulmonary exercise testing in pulmonary hypertension associated with congenital heart disease vs. other forms of pulmonary hypertension: physiological insights

Presentation thumbnail

The occurence of Heart failure result in low weight at birth in woman with congenital heart disease

Doctor S. Bele (Tirana, AL)

Presentation thumbnail

Relationship between serotonergic-modulating psycoactive treatments and 24-hour Cheyne-Stokes respiration occurrence in systolic heart failure.

Doctor G. Mirizzi (Pisa, IT)

Presentation thumbnail

The association between markers of fibrosis and myocardial dyssynchrony in patients with CHF

Professor O. Bilchenko (Kharkiv, UA)

Presentation thumbnail

Circulating biomarkers of inflammation and left ventricular hypertrophy in patients with heart failure with preserved ejection fraction

Professor O. Bilchenko (Kharkiv, UA)

Access the full session

Session thumbnail

Poster Session 2 - Chronic Heart Failure – Pathophysiology and Mechanisms

The Event

Heart Failure 2018

26 May - 29 May 2018

You may be interested in

Congress Presentation

Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.

Congress Presentation

Clinical characteristics and long-term prognosis of patients with heart failure with reduced, mildly reduced, and preserved left ventricular ejection fraction secondary to Chagas cardiomyopathy

Congress Session

Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources